Effect of Rosiglitazone on Bone Metabolism

Phase 4

Completed

• Conditions: ormal Post Menopausal Women; Normal Post Menopausal Women; Reproductive Health and Childbirth - Menstruation and menopause

• Registration Number: ACTRN12605000218695
• Lead Sponsor: Associate Professor A Grey

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Postmenopausal 5 yrs or more.

Exclusion Criteria

Renal impairment (serum creatinine >0.15 mmol/L), congestive heart failure, chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP > 2x normal limit, diabetes mellitus, primary hyperparathyroidism, > 2 hospital admission within 6 months of study entry. Use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding 12 months, current or past use of bisphosphonate therapy, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism, current or past use of thiazolidinediones.

Study & Design

• Study Type: Interventional
• Study Design: Not specified